[1] LI Q, LI X, WANG J, et al.Diagnosis and Treatment for Hyperuricemia and Gout: a Systematic Review of Clinical Practice Guidelines and Consensus Statements[J]. BMJ Open, 2019, 9(8): e026677. [2] China National Health Association, Severe Metabolic Disease Branch, Multi-Disciplinary Expert Task Force on Hyperuricemia and Its Related Diseases. China Multi-Disciplinary Expert Consensus on Diagnosis and Treatment of Hyperuricemia and Related Diseases (2023 edition)[J]. Chinese Journal of Practical Internal Medicine(中国实用内科杂志), 2023, 43(6): 461-480. [3] FANG Y, YANG B.The Impact of Benzbromarone on Renal Function and Serum BUA Levels in Patients with Gout and Hyperuricemia[J]. Jilin Medical Journal(吉林医学), 2022, 43(5): 1276-1278. [4] KADOWAKI D, SAKAGUCHI S, MIYAMOTO Y, et al.Direct Radical Scavenging Activity of Benzbromarone Provides Beneficial Antioxidant Properties for Hyperuricemia Treatment[J]. Biological and Pharmaceutical Bulletin, 2015, 38(3): 487-492. [5] WU F, CHEN L, DU Y.Comparison of the Efficacy and Safety of Benzbromarone and Febuxostat in Gout and Hyperuricemia: a Systematic Review and Meta-Analysis[J]. Clinical Rheumatology, 2024, 43(5): 1745-1754. [6] JIA E, ZHU H, GENG H, et al.Effect of Alkalized Urine on Renal Calculi in Patients with Gout: a Protocol for a Placebo-Controlled, Double-Blinded Randomized Controlled Trial[J]. Trials, 2021, 22(1): 743. [7] WANG JH.Why Urate-Lowering Drugs often Need to Be Combined with Sodium Bicarbonate[J]. Jiangsu Journal of Health Care(江苏卫生保健), 2021 (1): 30. [8] YANG L, HAN Y, SHEN Q, et al.Review and Comment Rules for National Key Monitoring Drug Prescriptions (Medical Orders)[J]. China Pharmacy(中国药房), 2023, 34(21): 2561-2577. [9] WANG FH.Regulation and Molecular Mechanism of Flavonoid Compounds on Transporter Oat3, Regulation and Molecular Mechanism of Alkaloid Compounds on Transporter Glut1[D]. Beijing: Peking Union Medical College, 2023. [10] THAKUR A, METTU VS, SINGH DK, et al.Effect of Probenecid on Blood Levels and Renal Elimination of Furosemide and Endogenous Compounds in Rats: Discovery of Putative Organic Anion Transporter Biomarkers[J]. Biochemical Pharmacology, 2023, 218: 115867. [11] Psoriasis Professional Committee of Dermatology and Venereology Branch of Chinese Medical Association. the Expert Consensus on Methotrexate in the Treatment of Psoriasis[J]. Journal of Clinical Dermatology(临床皮肤科杂志), 2022, 51(2): 108-117. [12] COLEMAN GB, DALBETH N, FRAMPTON C, et al.Long-Term Follow-Up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People with Gout[J]. The Journal of Rheumatology, 2022, 49(12): 1372-1378. [13] WANG SN, HE X, TONG LJ, et al.Correlation Analysis between Severe Cutaneous Adverse Reactions Caused by Allopurinol and Hla-B*5801 Allele in Various Ethnic Groups of Inner Mongolia[J]. Journal of Medicine & Pharmacy of Chinese Minorities(中国民族医药杂志), 2020, 26(9): 68-69. [14] KANG DY, YUN J, LEE SY, ET AL.A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea[J]. The Journal of Allergy and Clinical Immunology: In Practice, 2021, 9(2): 929-936. [15] ZHANG YY.Correlation between Allopurinol HLA-B*5801 Gene Detection and Traditional Chinese Medicine Constitution in Patients with Gout[D]. Inner Mongolia: Inner Mongolia Medical University, 2023. [16] ZHENG XZ.Comparative Efficacy of Allopurinol and Febuxostat in Chronic Renal Failure with Hyperuricemia[J]. Henan Medical Research(河南医学研究), 2020, 29(28): 5282-5284. [17] YANG F.Effect and Safety Study of Febuxostat in Treatment of Early, Middle and Late Stage Patients with Chronic Kidney Disease[J]. Smart Healthcare(智慧健康), 2024, 10(19): 118-120, 127. [18] LIU Y, LI SQ, LIU B, et al.Comparative Study on the Efficacy and Safety of Febuxostat and Allopurinol in the Treatment of Elderly Patients with Hyperuricemia[J]. Chinese Journal of Clinical Healthcare(中国临床保健杂志), 2020, 23(5): 607-612. [19] WANG M, ZHANG Y, ZHANG M, et al.The Major Cardiovascular Events of Febuxostat Versus Allopurinol in Treating Gout or Asymp-tomatic Hyperuricemia: a Systematic Review and Meta-Analysis[J]. Annals of Palliative Medicine, 2021, 10(10): 10327-10337. [20] FDA. FDA to Evaluate Increased Risk of Heart-Related Death and Death from All Causes with the Gout Medicine Febuxostat (Uloric)[EB/OL]. (2019-02-21)[2023-07-22]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warningincreased-risk-death-gout-medicine-uloric-febuxosta.html. [21] China Pharmaceutical Information Inquiry Platform. The Role of Rasburicase, The Dosage of Rasburicase_Adverse Reactions of Rasburicase[EB/OL].[2024-04-18]. https:// www.dayi.org.cn/drug/1152963.html. [22] PEI Y, LI Y, LIANG Y, et al.Evaluation of the Safety and Efficacy of Low-Dose Rasburicase in CriticallyⅢ Children with Haematological Malignancies[J]. International Journal of Clinical Pharmacy, 2020, 42(6): 1440-1446. [23] KOBAYASHI S, YASU T, AKAZAWA M.Survey of Anaphylaxis During Rasburicase Re-Administration in Patients with Hematological Malignancies Using a Japanese Claims Database[J]. Current Oncology, 2022, 29(12): 9826-9832. [24] ALLEN KC, CHAMPLAIN AH, COTLIAR JA, et al.Risk of Anaphylaxis with Repeated Courses of Rasburicase: a Research on Adverse Drug Events and Reports (Radar) Project[J]. Drug Safety, 2015, 38(2): 183-187. [25] ASGHARI KM, ZAHMATYAR M, SEYEDI F, et al.Gout: Global Epidemiology, Risk Factors, Comorbidities and Complications: a Narrative Review[J]. BMC Musculoskeletal Disorders, 2024, 25(1): 1047. [26] PARK HJ, YUN J, KANG DY, et al.Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions[J]. The Journal of Allergy and Clinical Immunology: In Practice, 2019, 7(8): 2739-2749. [27] Chinese Medical Association Nephrology Branch. Practice Guidelines for the Diagnosis and Treatment of Hyperuricemia in Chinese Patients with Kidney Diseases (2017 edition)[J]. National Medical Journal of China(中华医学杂志), 2017, 97(25): 1927-1936. [28] ZHANG W, DOHERTY M, BARDIN T, et al.EULAR Evidence Based Recommendations for Gout. Part II: Management. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)[J]. Annals of the Rheumatic Diseases, 2006, 65(10): 1312-1324. [29] SINGH JA, EDWARDS NL. Gout Management and Outcomes During the Covid-19 Pandemic: a Cross-Sectional Internet Survey[J]. Therapeutic Advances in Musculoskeletal Disease, 2020, 12: 1759720x20966124. [30] LIU Y, JARMAN JB, LOW YS, et al.A Widely Distributed Gene Cluster Compensates for Uricase Loss in Hominids[J]. Cell, 2023, 186(16): 3400-3413. [31] WANG M, FAN J, HUANG Z, et al.Causal Relationship between Gut Microbiota and Gout: a Two-Sample Mendelian Randomization Study[J]. Nutrients, 2023, 15(19): 4260. |